Skip to main content

Table 1 Baseline patient characteristics at the start of maintenance therapy

From: Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study

Characteristic All
(n = 120)
ICIs
(n = 38)
ICIs + Pem
(n = 82)
P
Age
  ≥ 65 53 (44.2) 20 (52.6) 33 (40.2) 0.204
  < 65 67 (55.8) 18 (47.4) 49 (59.8)  
Gender
 Male 85 (70.8) 27 (71.1) 58 (70.7) 0.971
 Female 35 (29.2) 11 (28.9) 24 (29.3)  
Smoking
 Yes 75 (62.5) 23 (60.5) 52 (63.4) 0.761
 No 45 (37.5) 15 (39.5) 30 (69.3)  
ECOG PS
 0 42 (35.0) 13 (34.2) 29 (35.3) 0.902
 1 78 (65.0) 25 (65.8) 53 (64.6)  
Brain metastasis
 Yes 17 (14.2) 3 (7.9) 14 (17.1) 0.180
 No 103 (85.8) 35 (92.1) 68 (82.9)  
Liver metastasis
 Yes 11 (9.2) 3 (7.9) 8 (9.8) 1.000
 No 109 (90.8) 35 (92.1) 74 (90.2)  
Intrathoracic metastasis
 Yes 79 (65.8) 26 (68.4) 53 (64.6) 0.684
 No 41 (34.2) 12 (31.6) 29 (35.4)  
Bone metastasis
 Yes 44 (36.7) 12 (31.6) 32 (39.0) 0.431
 No 76 (63.3) 26 (68.4) 50 (61.0)  
Platinum
 Cisplatin 33 (27.5) 10 (26.3) 23 (28.0) 0.843
 Carboplatin 87 (72.5) 28 (73.7) 59 (72.0)  
PD-L1 TPS
  < 1% 32 (26.7) 10 (26.3) 22 (26.8) 0.370
 1–49% 21 (17.5) 4 (10.5) 17 (20.7)  
  ≥ 50% 32 (26.7) 12 (31.6) 20 (24.3)
 Unkown 35 (29.2) 12 (31.5) 23 (28.0)
Response to induction therapy
 Partial response 55 (45.8) 12 (31.6) 43 (52.4) 0.033
 Stable disease 65 (54.2) 26 (68.4) 39 (47.6)  
 Cycles of induction therapy Median (range) 4 (4–6) 4 (4–6) 4 (4–6)
  1. ICIs Immune checkpoint inhibitors, Pem Pemetrexed, ECOG PS Eastern Cooperative Oncology Group Performance Status, PD-L1 TPS Programmed death ligand 1 tumour proportion score